Physician profile
John Lung
NPI 1952534844
$177,012.10
in general payments reported to CMS, 2019-2025
12 companies · $56K in 2025
The $56K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $38.46 · 2021: $3,900 · 2022: $24K · 2023: $43K · 2024: $49K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $149K · Food and Beverage: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $148,650.00 |
| Food and Beverage | $225.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $148,650.00 | 2023-2025 | |
| Csl Behring | $27,900.00 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $114.30 | 2019-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $109.99 | 2019-2024 | Austedo Xr, Uzedy |
| Alkermes, INC. | $62.42 | 2019-2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $45.08 | 2022-2024 | Invega Sustenna |
| Ironshore Pharmaceuticals INC. | $36.59 | 2019 | |
| Vanda Pharmaceuticals INC. | $26.24 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $25.23 | 2020-2022 | |
| Corium, LLC | $16.03 | 2024 | Azstarys |
| Shire North American Group INC | $13.47 | 2019 | |
| Indivior INC. | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.